ENDPOINTS

Exclusive: Allay reaches $57.5M Series D milestone for Phase 2b pain trial

NEW YORK — Allay Therapeutics has corralled $57.5 million in a Series D to help it complete a Phase 2b pain trial and gear up for a Phase 3 next summer, the biotech exclusively told ...

Jun 5, 2025 - 12:04
 0
Exclusive: Allay reaches $57.5M Series D milestone for Phase 2b pain trial
NEW YORK — Allay Therapeutics has corralled $57.5 million in a Series D to help it complete a Phase 2b pain trial and gear up for a Phase 3 next summer, the biotech exclusively told ...
Read More

Tags:

Previous Article

This cloud storage platform lets you launch branded file-sharing portals like mi...

Next Article

Amplify raises $200M biotech fund, hires Elliot Hershberg as partner

Related Posts

Ex-FDA chief Robert Califf thinks RFK Jr.'s vaccine opinions are relevant

Ex-FDA chief Robert Califf thinks RFK Jr.'s vaccine opi...

May 14, 2025  0

Will the FDA approve Moderna's next-gen Covid shot?

Will the FDA approve Moderna's next-gen Covid shot?

May 28, 2025  0

Exclusive: ProteinQure raises $11M Series A for peptide drugs

Exclusive: ProteinQure raises $11M Series A for peptide...

May 27, 2025  0